Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
QIAGEN logo — Provider of molecular Sample to Insight solutions

QIAGEN

Provider of molecular Sample to Insight solutions

Founded 1984 The Netherlands The Netherlands 5488 employees IPO Total: $504.60M

General Information

Company Name QIAGEN
Founded Year 1984
Location The Netherlands The Netherlands
Employees 5488
Funding Stage IPO
Business Model B2B, D2C, SaaS
Revenue Model Product Sales, Service Fee, Licensing
Social

BounceWatch is an independent company data service, not affiliated with QIAGEN. To contact QIAGEN, visit qiagen.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About QIAGEN

QIAGEN, founded in 1984, is a dominant player in the biomolecular industry with its mission encapsulated in the slogan: Provider of molecular Sample to Insight solutions. Headquartered in The Netherlands, the company specializes in isolating and processing essential biomolecules such as DNA, RNA, and proteins from various samples.

The company's technologies include advanced assay methods, bioinformatics software, and seamless automation solutions, collectively facilitating the transformation of molecular data into actionable insights. Serving over 500,000 clients globally, QIAGEN caters to sectors like Molecular Diagnostics and Life Sciences, supporting endeavors in human healthcare and industrial applications.

As of the end of 2021, QIAGEN employed over 6,000 individuals across more than 35 locations worldwide. The company’s recent financial momentum was underscored by a significant $500.00M Post IPO Convertible investment on 01 September 2024, indicating robust investor confidence in its growth trajectory.

Taxonomy: Molecular Sample to Insight solutions, Sample technologies, DNA/RNA/Proteins isolation, Assay technologies, Bioinformatics software, Automation solutions, Molecular Diagnostics, Life Sciences, Human healthcare, Pharma R&D, Forensics, Food safety testing, Veterinary medicine, Pharmaceutical research, Biomolecular analysis

Services & Products

IVD Sample Extraction Automation
Clinical Nucleic Acid Extraction
Digital PCR Systems
Hybrid Capture Technology
MiRNA Discovery and Validation

Target Customers

Clinical Labs Biotech and Pharma Companies Research Institutions Forensic Labs Oncology Researchers

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Convertible $500.00M -
01 Sep 2024
Post-IPO Equity Undisclosed 1
Westpac
Westpac
01 Aug 2023
Grant $4.00M 2
US Department of War, US Department of Health and Human Services
01 Oct 2021
Grant $600.00K 1
HHS Administration for Strategic Preparedness and Response
01 Mar 2020
IPO Undisclosed -
01 Jul 1996
IPO Undisclosed -
01 Jan 1996
Spinout Undisclosed 3
University of Düsseldorf, Leibniz Association +1
01 Jan 1984

QIAGEN Alternatives & Competitors

View All Alternatives
QIAGEN vs
Slone Partners
Slone Partners United States

Executive search and talent advisory firm for life sciences and healthcare

62 employees
Biotechnology, Health Care
QIAGEN vs
IntegenX, Inc.
IntegenX, Inc. United States

Automation systems for accurate microsample preparation and analysis in life sciences, bringing adva...

Debt Financing
21 employees
Biotechnology, Health Care
QIAGEN vs
HP Health Solutions Germany GmbH
HP Health Solutions Germany GmbH Germany

GNA Biosolutions | Breaking the limits of molecular diagnostics

Series C
28 employees
Biotechnology, Health Care
View all alternatives

FAQ About QIAGEN

Provider of molecular Sample to Insight solutions
QIAGEN was founded in 1984.
QIAGEN is headquartered in The Netherlands.
QIAGEN has a B2B, D2C and SaaS business model. Its revenue comes from Product Sales, Service Fee and Licensing.
QIAGEN has approximately 5488 employees.
QIAGEN has completed 7 funding rounds, raising a total of $504.60M. The latest funding stage is IPO.
QIAGEN offers: IVD Sample Extraction Automation, Clinical Nucleic Acid Extraction, Digital PCR Systems, Hybrid Capture Technology, MiRNA Discovery and Validation.
Top alternatives and competitors to QIAGEN include Slone Partners, IntegenX, Inc., HP Health Solutions Germany GmbH, Argonaut Manufacturing Services Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
QIAGEN and Slone Partners are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for QIAGEN, https://bouncewatch.com/company/qiagen, updated 2 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes